MiR-372 down-regulates the oncogene ATAD2 to influence hepatocellular carcinoma proliferation and metastasis

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Wu, Gang ^a   Liu, Haiyang ^a   He, Hui ^a   Wang, Yawei ^a   Lu, Xiaojun ^a   Yu, Yanqiu ^a   Xia, Shuguan ^a   Meng, Xiangyu ^a   Liu, Yongfeng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; LUCIFERASE; MICRORNA; MICRORNA 372; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ADENOSINE TRIPHOSPHATASE; ALPHA CATENIN; APC PROTEIN; ATAD2 PROTEIN, HUMAN; CTNNA1 PROTEIN, HUMAN; DNA BINDING PROTEIN; MIRN372 MICRORNA, HUMAN; SMALL INTERFERING RNA;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CTNNA1 GENE; DOWN REGULATION; FEMALE; FLUORESCENCE ANALYSIS; G1 PHASE CELL CYCLE CHECKPOINT; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; ONCOGENE ATAD2; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTO ONCOGENE; UPREGULATION; AGED; BINDING SITE; CANCER GRADING; CELL MOTION; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; TUMOR VOLUME;

3' UNTRANSLATED REGIONS; ADENOMATOUS POLYPOSIS COLI PROTEIN; ADENOSINE TRIPHOSPHATASES; ADULT; AGED; ALPHA CATENIN; BASE SEQUENCE; BINDING SITES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; RNA, SMALL INTERFERING; TUMOR BURDEN;

EID: 84898597555     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-107     Document Type: Article

References (32)

1. But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008, 14:1652-1656. 10.3748/wjg.14.1652, 2695904, 18350595.
2. Chen HW, Huang XD, Li HC, He S, Ni RZ, Chen CH, Peng C, Wu G, Wang GH, Wang YY, Zhao YH, Zhang YX, Shen AG, Wang HM. Expression of FOXJ1 in hepatocellular carcinoma: correlation with patients' prognosis and tumor cell proliferation. Mol Carcinog 2013, 52:647-659. 10.1002/mc.21904, 22488567.
3. He H, Wu G, Li W, Cao Y, Liu Y. CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis. Diagn Mol Pathol 2012, 21:143-149. 10.1097/PDM.0b013e318249fd8b, 22847158.
4. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003, 22:5093-5107. 10.1038/sj.onc.1206557, 12910247.
5. Feng JT, Shang S, Beretta L. Proteomics for the early detection and treatment of hepatocellular carcinoma. Oncogene 2006, 25:3810-3817. 10.1038/sj.onc.1209551, 16799622.
6. Zou JX, Revenko AS, Li LB, Gemo AT, Chen HW. ANCCA, an estrogen-regulated AAA + ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci U S A 2007, 104:18067-18072. 10.1073/pnas.0705814104, 2084297, 17998543.
7. Ciro M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, Nucifero P, Pacchiana G, Capra M, Christensen J, Helin K. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res 2009, 69:8491-8498. 10.1158/0008-5472.CAN-09-2131, 19843847.
8. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511. 10.1038/35000501, 10676951.
9. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, Van De Rijn M, Botstein D, Brown PO. Gene expression patterns in human liver cancers. Mol Biol Cell 2002, 13:1929-1939. 10.1091/mbc.02-02-0023., 117615, 12058060.
10. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, Zhou YX, Varnholt H, Smith B, Gadd M, Chatfield E, Kessler J, Baer TM, Erlander MG, Sgroi DC. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 2003, 100:5974-5979. 10.1073/pnas.0931261100, 156311, 12714683.
11. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, Ladd C, Reich M, Latulippe E, Mesirov JP, Poggio T, Gerald W, Loda M, Lander ES, Golub TR. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 2001, 98:15149-15154. 10.1073/pnas.211566398, 64998, 11742071.
12. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 10.1038/415530a, 11823860.
13. Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V, Barbry P, Debernardi A, Brambilla C, Brambilla E, Rousseaux S, Khochbin S. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene 2010, 29:5171-5181. 10.1038/onc.2010.259, 20581866.
14. Huang Q, Lin B, Liu H, Ma X, Mo F, Yu W, Li L, Li H, Tian T, Wu D, Shen F, Xing J, Chen ZN. RNA-Seq analyses generate comprehensive transcriptomic landscape and reveal complex transcript patterns in hepatocellular carcinoma. PLoS One 2011, 6:e26168. 10.1371/journal.pone.0026168, 3197143, 22043308.
15. Zhou L, Rui JA, Ye DX, Wang SB, Chen SG, Qu Q. Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection. World J Surg 2008, 32:1748-1756. 10.1007/s00268-008-9615-8, 18493820.
16. Zeng L, Zhou MM. Bromodomain: an acetyl-lysine binding domain. FEBS Lett 2002, 513:124-128. 10.1016/S0014-5793(01)03309-9, 11911891.
17. Marmorstein R, Berger SL. Structure and function of bromodomains in chromatin-regulating complexes. Gene 2001, 272:1-9. 10.1016/S0378-1119(01)00519-4, 11470504.
18. Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX, Cardiff RD, Borowsky AD, Chen HW. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res 2010, 70:9402-9412. 10.1158/0008-5472.CAN-10-1199, 2982862, 20864510.
19. Fouret R, Laffaire J, Hofman P, Beau-Faller M, Mazieres J, Validire P, Girard P, Camilleri-Broet S, Vaylet F, Leroy-Ladurie F, Soria JC, Fouret P. A comparative and integrative approach identifies ATPase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma. Clin Cancer Res 2012, 18:5606-5616. 10.1158/1078-0432.CCR-12-0505, 22914773.
20. Colnot S, Decaens T, Niwa-Kawakita M, Godard C, Hamard G, Kahn A, Giovannini M, Perret C. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci U S A 2004, 101:17216-17221. 10.1073/pnas.0404761101, 535370, 15563600.
21. Rimm DL, Koslov ER, Kebriaei P, Cianci CD, Morrow JS. Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex. Proc Natl Acad Sci U S A 1995, 92:8813-8817. 10.1073/pnas.92.19.8813, 41057, 7568023.
22. Koslov ER, Maupin P, Pradhan D, Morrow JS, Rimm DL. Alpha-catenin can form asymmetric homodimeric complexes and/or heterodimeric complexes with beta-catenin. J Biol Chem 1997, 272:27301-27306. 10.1074/jbc.272.43.27301, 9341178.
23. Vasioukhin V, Bauer C, Degenstein L, Wise B, Fuchs E. Hyperproliferation and defects in epithelial polarity upon conditional ablation of alpha-catenin in skin. Cell 2001, 104:605-617. 10.1016/S0092-8674(01)00246-X, 11239416.
24. Pirinen RT, Hirvikoski P, Johansson RT, Hollmen S, Kosma VM. Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J Clin Pathol 2001, 54:391-395. 10.1136/jcp.54.5.391, 1731412, 11328840.
25. Nakopoulou L, Gakiopoulou-Givalou H, Karayiannakis AJ, Giannopoulou I, Keramopoulos A, Davaris P, Pignatelli M. Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival. Histopathology 2002, 40:536-546. 10.1046/j.1365-2559.2002.01392.x, 12047765.
26. Kadowaki T, Shiozaki H, Inoue M, Tamura S, Oka H, Doki Y, Iihara K, Matsui S, Iwazawa T, Nagafuchi A, et al. E-cadherin and alpha-catenin expression in human esophageal cancer. Cancer Res 1994, 54:291-296.
27. Endo K, Ueda T, Ueyama J, Ohta T, Terada T. Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. Hum Pathol 2000, 31:558-565. 10.1053/hp.2000.6683, 10836294.
28. Ihara A, Koizumi H, Hashizume R, Uchikoshi T. Expression of epithelial cadherin and alpha- and beta-catenins in nontumoral livers and hepatocellular carcinomas. Hepatology 1996, 23:1441-1447.
29. Wijnhoven BP, Dinjens WN, Pignatelli M. E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 2000, 87:992-1005. 10.1046/j.1365-2168.2000.01513.x, 10931041.
30. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Looijenga LH, Agami R. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006, 124:1169-1181. 10.1016/j.cell.2006.02.037, 16564011.
31. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999, 400:464-468. 10.1038/22780, 10440377.
32. Tian RQ, Wang XH, Hou LJ, Jia WH, Yang Q, Li YX, Liu M, Li X, Tang H. MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis. J Biol Chem 2011, 286:25556-25563. 10.1074/jbc.M111.221564, 3138314, 21646351.